用产品替代治疗先天性缺陷:胆酸合成先天性缺陷的例子
Peter T Clayton1, Rohit Hirachan2, Elaine Murphy3
1Inborn Errors of Metabolism, Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, UK.
Journal of inherited metabolic disease
|August 23, 2025
概括
使用胆汁酸 (CDCA) 和胆汁酸 (CA) 等胆汁酸的产品替代疗法可以有效地治疗影响胆汁酸合成的某些先天性代谢错误,特别是婴儿肝脏疾病和神经症状.
科学领域:
- 生物化学
- 代谢疾病
- 遗传学
背景情况:
- 代谢的先天性错误通常源于代谢物合成的缺陷,导致由于缺乏必需化合物的疾病.
- 胆酸合成缺陷,如3β-基-Δ5-C27-类固醇脱酶缺乏,可能导致严重的婴儿胆固醇性肝病.
- 其他代谢障碍,包括脑质瘤 (CTX) 和过氧体生物发生障碍,伴有肝脏和/或神经疾病.
研究的目的:
- 探索"产品替代"策略在先天代谢错误中的治疗潜力.
- 突出陈酸 (CDCA) 和胆酸 (CA) 在治疗特定胆酸合成缺陷和相关肝脏疾病中的有效性.
- 讨论胆汁酸和尿酸在各种新陈代谢疾病的神经和肝脏表现的使用.
主要方法:
- 对影响胆酸合成和过氧体功能的各种先天代谢错误的临床表现和治疗结果的审查.
- 分析作为替代疗法使用的氧化 (CDCA) 和胆酸 (CA) 的有效性.
- 对3β-基-Δ5-C27-类固醇脱酶缺乏症,CTX和过氧体疾病等特定疾病的治疗方法的检查.
主要成果:
- CDCA和/或CA在治疗由3β- 基- Δ5- C27- 类固醇脱酶缺乏引起的婴儿胆固醇性肝病方面非常有效.
- CDCA在治疗与大脑肌瘤 (CTX) 相关的神经疾病方面表现出显著的疗效.
- 用CDCA和CA治疗可降低C27胆酸水平,可变的临床改善报告.
结论:
- 用胆汁酸替代药物治疗是治疗特定的先天代谢错误的可行和有效方法.
- 早期诊断和使用CDCA和/或CA的干预可以显著改善婴儿肝病和神经症状的结果.
- 需要进一步的研究,以充分阐明胆酸治疗对某些过氧体疾病和其他代谢疾病的益处.
相关概念视频
Inborn Errors of Metabolism
241
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
241
Protein Import into the Peroxisomes
3.6K
Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
3.6K
Phase II Reactions: Miscellaneous Conjugation Reactions
111
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
111
Hepatic Drug Excretion: Enterohepatic Cycling
1.7K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.7K
Drug Biotransformation: Overview
2.9K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.9K
Pedigree Analysis
85.1K
Overview
85.1K


